Item no. |
HY-B0442A-50mg |
Manufacturer |
MedChem Express
|
CASRN |
224785-91-5 |
Amount |
50 mg |
Quantity options |
100 mg
10mM/1mL
200 mg
25 mg
50 mg
|
Specific against |
other |
Purity |
99.48 |
Citations |
Life Sci. 15 November 2022, 120992.<br/>Anim Cells Syst (Seoul). 2019 May 16;23(3):155-163.<br/>[1]Ashour AE, et al. Vardenafil dihydrochloride. Profiles Drug Subst Excip Relat Methodol. 2014;39:515-544.<br/>[2]Saenz de Tejada I, et al. The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil. Int J Impot Res. 2001;13(5):282-290.<br/>[3]Gresser U, et al. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil--review of the literature. Eur J Med Res. 2002 Oct 29. 7(10):435-46. <br/>[4]Oudot A, et al. Combination of BAY 60-4552 and vardenafil exerts proerectile facilitator effects in rats with cavernous nerve injury: a proof of concept study for the treatment of phosphodiesterase type 5 inhibitor failure. Eur Urol. 2011 Nov. 60(5):1020-6. <br/>[5]Ahmed N, et al. Hepatoprotective role of vardenafil against experimentally induced hepatitis in mice. J Biochem Mol Toxicol. 2017 Mar. 31(3). <br/>[6]Bódi B, et al. Long-Term PDE-5A Inhibition Improves Myofilament Function in Left and Right Ventricular Cardiomyocytes through Partially Different Mechanisms in Diabetic Rat Hearts. Antioxidants (Basel). 2021 Nov 6. 10(11):1776. |
Smiles |
CCCC1=NC(C)=C2N1N=C(C(C=C(S(=O)(N3CCN(CC)CC3)=O)C=C4)=C4OCC)NC2=O.Cl |
Available |
|
Product Description |
Vardenafil hydrochloride is a selective and orally active inhibitor of phosphodiesterase-5 (PDE5), with an IC50 of 0.7 nM. Vardenafil hydrochloride shows inhibitory towards PDE1, PDE6 with IC50s of 180 nM, and 11 nM, while IC50s are >1000 nM for PDE3 and PDE4[1]. Vardenafil hydrochloride competitively inhibits cyclic guanosine monophosphate (cGMP) hydrolysis and thus increases cGMP levels[2]. Vardenafil hydrochloride can be used for the research of erectile dysfunction, hepatitis, diabetes[1]-[6]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture) |
Shipping |
Room Temperature |
Manufacturers Applications |
COVID-19-immunoregulation |
MolecularWeight |
525.06 |
Clinical Information |
Launched |
Manufacturers Research Area |
Endocrinology; Metabolic Disease; Inflammation/Immunology |
Solubility |
DMSO : 100 mg/mL (ultrasonic)|H2O : ≥ 100 mg/mL |
Target |
Endogenous Metabolite; Phosphodiesterase (PDE) |
Manufacturers Target |
Endogenous Metabolite; Phosphodiesterase (PDE) |
Isoform |
PDE1; PDE3; PDE4; PDE5; PDE6 |
Manufacturers Pathway |
Metabolic Enzyme/Protease |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.